
Jason N Barreto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8208574/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Prospective evaluation of highâ€dose methotrexate pharmacokinetics in adult patients with lymphoma usingÂnovel determinants of kidney function. Clinical and Translational Science, 2022, 15, 105-117.	3.1	7
2	Variation in Clinical Practice and Attitudes on Antibacterial Management of Fever and Neutropenia in Patients With Hematologic Malignancy: A Survey of Cancer Centers Across the United States. Open Forum Infectious Diseases, 2022, 9, ofac005.	0.9	10
3	A Prospective Evaluation of Novel Renal Biomarkers in Patients With Lymphoma Receiving High-Dose Methotrexate. Kidney International Reports, 2022, 7, 1690-1693.	0.8	3
4	Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. Supportive Care in Cancer, 2021, 29, 5293-5301.	2.2	10
5	Lack of drug interaction between levetiracetam and highâ€dose methotrexate in patients with lymphoma. Pharmacotherapy, 2021, 41, 430-439.	2.6	7
6	Incidence of Pneumocystis jirovecii pneumonia utilizing a polymerase chain reactionâ€based diagnosis in patients receiving bendamustine. Cancer Medicine, 2021, 10, 5120-5130.	2.8	2
7	The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor <scp>T</scp> â€cell therapy. American Journal of Hematology, 2021, 96, E399-E402.	4.1	14
8	Effect of a multimodal multidisciplinary training program on pharmacy residents' knowledge and confidence toward research and biostatistics. Currents in Pharmacy Teaching and Learning, 2020, 12, 20-26.	1.0	8
9	Cystatin C: A Primer for Pharmacists. Pharmacy (Basel, Switzerland), 2020, 8, 35.	1.6	32
10	Incidence, clinical presentation, and outcomes of Pneumocystis pneumonia when utilizing Polymerase Chain Reaction-based diagnosis in patients with Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 2622-2629.	1.3	2
11	The Utility of Granulocyte Colony Stimulating Factor in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy with Axicabtagene Ciloleucel. Blood, 2020, 136, 23-25.	1.4	Ο
12	QT prolongation in patients with acute leukemia or high-risk myelodysplastic syndrome prescribed antifungal prophylaxis during chemotherapy-induced neutropenia. Leukemia and Lymphoma, 2019, 60, 3512-3520.	1.3	6
13	Impact of time to antibiotic on hospital stay, intensive care unit admission, and mortality in febrile neutropenia. Supportive Care in Cancer, 2019, 27, 4171-4177.	2.2	28
14	Navigating the Muddy Waters of Vancomycin Nephrotoxicity. Mayo Clinic Proceedings, 2019, 94, 1-3.	3.0	4
15	Relationship of Ganciclovir Therapeutic Drug Monitoring with Clinical Efficacy and Patient Safety. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	39
16	Incidence and Outcomes of Pneumocystis pneumonia When Utilizing PCR-Based Diagnosis in Patients with Hodgkin Lymphoma Receiving Intensive Chemotherapy. Blood, 2019, 134, 4052-4052.	1.4	1
17	Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate. Blood, 2019, 134, 1621-1621.	1.4	0
18	Early Corticosteroids for Pneumocystis Pneumonia in Adults Without HIV Are Not Associated With Better Outcome. Chest, 2018, 154, 636-644.	0.8	58

JASON N BARRETO

#	Article	IF	CITATIONS
19	A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia. Journal of Antimicrobial Chemotherapy, 2018, 73, 204-211.	3.0	12
20	Incorporating Cystatin C to Predict Methotrexate Elimination in Patients with CNS Lymphoma and Suspicious Renal Function. Case Reports in Hematology, 2018, 2018, 1-5.	0.4	8
21	Cystatin C–Guided Vancomycin Dosing in Critically III Patients: AÂQuality Improvement Project. American Journal of Kidney Diseases, 2017, 69, 658-666.	1.9	60
22	Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. Leukemia and Lymphoma, 2017, 58, 2588-2597.	1.3	12
23	Characterization of Admission Types in Medically Hospitalized Patients Prescribed Clozapine. Psychosomatics, 2017, 58, 164-172.	2.5	30
24	Relationship of Sulfamethoxazole Therapeutic Drug Monitoring to Clinical Efficacy and Toxicity. Therapeutic Drug Monitoring, 2016, 38, 319-326.	2.0	17
25	Low incidence of pneumocystis pneumonia utilizing PCRâ€based diagnosis in patients with Bâ€cell lymphoma receiving rituximabâ€containing combination chemotherapy. American Journal of Hematology, 2016, 91, 1113-1117.	4.1	24
26	A Comparison of Levofloxacin and Oral Third Generation Cephalosporins As Antibacterial Prophylaxis in Acute Myeloid Leukemia (AML) during Chemotherapy-Induced Neutropenia. Blood, 2016, 128, 3986-3986.	1.4	0
27	Clozapine therapy throughout myelosuppressive chemotherapy: regulations without standardization. Psycho-Oncology, 2015, 24, 1581-1585.	2.3	7
28	Emerging Issues in Gram-Negative Bacterial Resistance. Mayo Clinic Proceedings, 2015, 90, 395-403.	3.0	161
29	Clofarabine Based Chemotherapy in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma-a Single Institution Experience. Blood, 2015, 126, 4910-4910.	1.4	0
30	Serum Peak Sulfamethoxazole Concentrations Demonstrate Difficulty in Achieving a Target Range: A Retrospective Cohort Study. Current Therapeutic Research, 2014, 76, 104-109.	1.2	16
31	Antineoplastic Agents and the Associated Myelosuppressive Effects. Journal of Pharmacy Practice, 2014, 27, 440-446.	1.0	95
32	Supratherapeutic International Normalized Ratios in Warfarin-Treated Patients Who Receive a Highly Potentiating Antimicrobial Course. JAMA Internal Medicine, 2014, 174, 1200.	5.1	2
33	Cefpodoxime for Antimicrobial Prophylaxis in Neutropenia: A Retrospective Case Series. Clinical Therapeutics, 2014, 36, 976-981.	2.5	12
34	The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. American Journal of Hematology, 2013, 88, 283-288.	4.1	42
35	Cost-Effectiveness Of Antithrombin Repletion In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy; A Single Center Experience. Blood, 2013, 122, 1732-1732.	1.4	1
36	Hepatic and Metabolic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. Blood, 2013, 122, 1405-1405.	1.4	0

#	Article	IF	CITATIONS
37	Thromboembolic and Hemorrhagic Complications In Adult Patients With Acute Lymphoblastic Leukemia (ALL) Treated With Asparaginase-Containing Combination Chemotherapy: A Single Center Experience. Blood, 2013, 122, 3873-3873.	1.4	1
38	Characterization of Bacterial Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients Who Received Prophylactic Levofloxacin With Either Penicillin or Doxycycline. Mayo Clinic Proceedings, 2010, 85, 711-718.	3.0	41
39	The essential research curriculum for doctor of pharmacy degree programs – 2021. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	4